HIGHBuilt-inPipeline
lead product candidates (CLN-978, CLN-049, zipalertinib)
“10-K Item 1A: 'We are early in our development efforts, with the exception of zipalertinib, and are substantially dependent on our lead product candidates.'”
CGEM · Concentration risk · 10-K extracted
Cullinan Therapeutics (CGEM) concentration risks
Updated
The most significant concentration Cullinan Therapeutics discloses is lead product candidates (CLN-978, CLN-049, zipalertinib), classified HIGH by disclosed size. Below: the full set from the latest 10-K — verbatim quotes, filing references, and a synthesis of what these exposures mean together.
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Source: Cullinan Therapeutics’s SEC Form 10-K filed — view the filing on SEC EDGAR ↗
At a glance
Disclosed-size breakdown · 2 disclosed concentrations
HIGH2
MEDIUM0
LOW0
Disclosed concentrations
Each card carries a disclosed-size chip (HIGH / MEDIUM / LOW — how large the exposure is as a share of revenue, not how dangerous it is) and a nature tag: Built-in(the company’s own model, geography, or products) or Outside party (an external customer, supplier, or distributor it relies on).
HIGHOutside partyCounterparty
Taiho Pharmaceutical
“10-K Item 1: 'we are collaborating with a Taiho affiliate to develop zipalertinib for the treatment of a genetically defined subset of patients with NSCLC, and Taiho will commercialize zipalertinib.'”
TrendMatrix Research · concentration synthesis
What these concentrations mean together
updated 2026-07-06Cullinan Therapeutics' risk profile is concentrated in exactly the way expected of an early-stage biotech: the company is substantially dependent on its lead product candidates — CLN-978, CLN-049, and zipalertinib — with the exception of zipalertinib still early in development, a high-level, structural concentration inherent to a pipeline this narrow. Compounding that is a counterparty dependency: zipalertinib is being developed in collaboration with a Taiho Pharmaceutical affiliate for a genetically defined NSCLC subset, with Taiho holding commercialization rights, also disclosed at a high level. These two exposures compound each other rather than diversify away: the one asset closest to commercialization is also the one where Cullinan does not control the eventual go-to-market. A setback in any of the three lead candidates would have an outsized effect given the absence of a broader marketed portfolio, and any disruption to the Taiho relationship would specifically threaten the most de-risked program. Both are well disclosed and typical of the sector, but together they define nearly all of the company's near-term value drivers.
For the engine’s reasoning on CGEM’s current verdict — including which dimensions drove the score — see the per-dimension breakdown.
Industry peers · Biotechnology
Peer concentration profile
| Symbol | Name | HIGH | MEDIUM | LOW | Total |
|---|---|---|---|---|---|
| ACAD | ACADIA Pharmaceuticals Inc. | 2 | 0 | 0 | 2 |
| CGEM● | Cullinan Therapeutics, Inc. | 2 | 0 | 0 | 2 |
| ABUS | Arbutus Biopharma Corporation | 1 | 1 | 0 | 2 |
| ABSI | Absci Corporation | 1 | 0 | 0 | 1 |
| ABCL | AbCellera Biologics Inc. | 0 | 0 | 0 | 0 |
| ACHV | Achieve Life Sciences, Inc. | 0 | 0 | 0 | 0 |
Concentration counts reflect items disclosed in each peer’s most recent 10-K; disclosed-size classification uses TrendMatrix’s internal 10-K extraction taxonomy.